Invasive Aspergillosis Clinical Trial
Official title:
ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study
To assessed the current situation and outcome of critically ill patients with invasive aspergillus infection.
| Status | Recruiting |
| Enrollment | 550 |
| Est. completion date | December 15, 2024 |
| Est. primary completion date | September 15, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Age>18 year-old - Diagosed as invasive aspergillus infection Exclusion Criteria: - Pregnant |
| Country | Name | City | State |
|---|---|---|---|
| China | Southeast University, Zhongda hospital | Nanjing | Jiangsu |
| Lead Sponsor | Collaborator |
|---|---|
| Southeast University, China |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | mortality | 28 day |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00163722 -
A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients
|
Phase 3 | |
| Completed |
NCT02394483 -
Single Ascending Oral Dose Study of F901318
|
Phase 1 | |
| Completed |
NCT01128907 -
Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients
|
N/A | |
| Completed |
NCT00404092 -
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
|
Phase 2 | |
| Recruiting |
NCT01386437 -
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
|
||
| Withdrawn |
NCT02912026 -
Radiolabelled IV and Oral Metabolism Study of F901318
|
Phase 1 | |
| Withdrawn |
NCT03076905 -
Pharmacokinetics of IV Formulation
|
Phase 1 | |
| Withdrawn |
NCT03095547 -
Drug/Drug Interactions With F901318
|
Phase 1 | |
| Completed |
NCT02737371 -
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT00836875 -
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
|
Phase 3 | |
| Active, not recruiting |
NCT00838643 -
Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
N/A | |
| Terminated |
NCT04876716 -
Azole-echinocandin Combination Therapy for Invasive Aspergillosis
|
Phase 3 | |
| Recruiting |
NCT05101187 -
Olorofim Aspergillus Infection Study
|
Phase 3 | |
| Enrolling by invitation |
NCT02104479 -
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
|
||
| Not yet recruiting |
NCT05707832 -
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
|
Phase 3 | |
| Recruiting |
NCT06382922 -
Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
|
||
| Terminated |
NCT02396225 -
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration
|
N/A | |
| Recruiting |
NCT00843804 -
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
|
N/A | |
| Completed |
NCT00334412 -
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
|
Phase 4 | |
| Completed |
NCT04550936 -
Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis
|